We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.87B
1-Year Est. Return 205.24%
This Fund
S&P 500
This Quarter Est. Return
-15.82%
1 Year Est. Return
+205.24%
3 Year Est. Return
+440.18%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.52B
AUM Growth
-$38.2M
Cap. Flow
+$249M
Cap. Flow %
16.37%
Top 10 Hldgs %
48.92%
Holding
59
New
7
Increased
23
Reduced
11
Closed
8

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$52.1M
2
NUVB icon
Nuvation Bio
NUVB
+$45M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$39.3M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$32.3M
5
NRIX icon
Nurix Therapeutics
NRIX
+$27.6M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$65.8M
2
KROS icon
Keros Therapeutics
KROS
+$28.1M
3
SAGE
Sage Therapeutics
SAGE
+$16.9M
4
ENTA icon
Enanta Pharmaceuticals
ENTA
+$14.1M
5
CRNX
Crinetics Pharmaceuticals
CRNX
+$9.75M

Sector Composition

Rank Sector Weight
1 Healthcare 95.07%
2 Miscellaneous 4.93%
3 Real Estate 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VIGL
51
DELISTED
Vigil Neuroscience
VIGL
$796K 0.05%
308,393
-80,748
-21% -$319K
ALNY icon
52
Alnylam Pharmaceuticals
ALNY
$32B
– –
-463,663
Closed -$65.8M
AUTL
53
Autolus Therapeutics
AUTL
$498M
– –
-382,559
Closed -$1.59M
ENTA icon
54
Enanta Pharmaceuticals
ENTA
$370M
– –
-198,730
Closed -$14.1M
NKTR icon
55
CALL
Nektar Therapeutics
NKTR
$2.3B
– –
-66,667
Closed -$5.39M
NKTR icon
56
PUT
Nektar Therapeutics
NKTR
$2.3B
– –
-33,333
Closed -$2.69M
RFL icon
57
Rafael Holdings
RFL
$107M
– –
-105,614
Closed -$261K
VERV
58
DELISTED
Verve Therapeutics
VERV
– –
-102,342
Closed -$2.33M
RXDX
59
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
– –
-245,000
Closed -$9.25M
1 2
3

Similar funds

PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
NP
NorthRock Partners Minneapolis, Minnesota $6.89B AUM 19.83% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $6.92B AUM 24.7% 1-Year Est. Return
RCWMU
Rothschild & Co Wealth Management (UK) London, United Kingdom $6.93B AUM 1.4% 1-Year Est. Return
CA
Cambridge Associates Boston, Massachusetts $6.93B AUM 17.96% 1-Year Est. Return
LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
CI
Cincinnati Insurance Fairfield, Ohio $6.94B AUM 20.24% 1-Year Est. Return

Deep Track Capital's Q2 2022 Portfolio in Review

As of Q2 2022, Deep Track Capital held 59 positions worth $1.52B, down 2.4% from $1.56B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Deep Track Capital deployed $249M of net new capital in Q2 2022, opening 7 new positions and adding to 23 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 654,365 shares worth $54.2M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Real Estate.

On the sell side, the largest reduction was Keros Therapeutics, an estimated $28.1M trimmed.

  • Deep Track Capital's largest Q2 2022 buy was BioMarin Pharmaceuticals: 654,365 shares worth $54.2M.
  • Deep Track Capital added most to Nuvation Bio in Q2 2022, an estimated $45M increase.
  • Deep Track Capital's biggest Q2 2022 reduction was Keros Therapeutics, cutting an estimated $28.1M.
  • Deep Track Capital fully exited Alnylam Pharmaceuticals in Q2 2022, selling an estimated $65.8M.
  • Deep Track Capital's ten largest holdings make up 49% of its $1.52B portfolio in Q2 2022.
  • Deep Track Capital opened 7 new positions and closed 8 in Q2 2022.
  • Deep Track Capital's portfolio value fell 2.4% quarter-over-quarter to $1.52B.

Based on Deep Track Capital's 13F filing for Q2 2022, filed 12 Aug 2022.